Maintenance dienogest therapy following adjuvant gonadotropin-releasing hormone agonist treatment after uterus-sparing surgery in adenomyosis: A retrospective cohort study

I‐San Chan, Hsu TF, Teh-Fu Hsu, Teh‐Fu Hsu, Ying‐Chu Shih, Shih YC, Ying-Chu Shih, Yen-Hou Chang, Yen‐Hou Chang, Chang YH, Peng‐Hui Wang, Yi‐Jen Chen
International Journal of Gynecology & Obstetrics · 2022 · vol. 161(3) , pp. 751–759 · doi:10.1002/ijgo.14635 · PMID:36527263 · W4311824214
article OA: closed CC0 ⤵ 6 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-07, 2026-07-08 ⓘ

Adjuvant GnRH-a followed by maintenance dienogest therapy significantly improved pain, hemoglobin, and uterine volume and reduced symptom recurrence compared to GnRH-a alone after uterus-sparing surgery for adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To investigate the safety and efficacy of adjuvant gonadotropin-releasing hormone agonist (GnRH-a) treatment followed by maintenance dienogest (DNG) therapy after uterus-sparing surgery. METHODS: Retrospective cohort study. A total of 190 patients with severe adenomyosis underwent uterus-sparing surgery between January 2010 and June 2020. Of these patients, 90 were analyzed. Forty-six patients (control group) received adjuvant 6-month GnRH-a therapy alone after uterus-sparing surgery, and 44 patients (maintenance group) received postoperative 6-month GnRH-a treatment followed by maintenance DNG therapy (2 mg/day orally). The median follow-up period was 18 months. The study was analyzed using generalized estimating equations. RESULTS: At baseline, the characteristics of patients in each group were comparable. Compared with the control group, the maintenance group had a significant improvement in the visual analog scale score of dysmenorrhea (P < 0.001), hemoglobin level (P = 0.004), and uterine volume (P = 0.004) from baseline to 18 months after uterus-sparing surgery. The symptom recurrence rate was significantly lower in the maintenance group than in the control group (4.6% vs. 37.0%, P < 0.001). CONCLUSIONS: The findings of this study suggest that combinatorial treatment with GnRH-a (adjuvant treatment) and DNG (maintenance therapy) represents a safe and effective short-term therapy after uterus-sparing surgery for adenomyosis.

My notes (saved in your browser only)

Condition tags

adenomyosisdysmenorrhea

MeSH descriptors

Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis

Funding

funders
[{'doi': '10.13039/501100008437', 'name': 'CSY China-International Hepatitis Research Foundation', 'awards': ['109021']}, {'doi': '10.13039/501100008437', 'name': 'CSY China-International Hepatitis Research Foundation', 'awards': ['110012']}, {'doi': '10.13039/100007225', 'name': 'Ministry of Science and Technology', 'awards': ['MOST 109‐2314‐B‐010‐041‐MY3']}, {'doi': '10.13039/100007225', 'name': 'Ministry of Science and Technology', 'awards': ['MOST 109‐2314‐B‐010‐042']}, {'doi': '10.13039/501100011912', 'name': 'Taipei Veterans General Hospital', 'awards': ['V109C‐097']}, {'doi': '10.13039/501100011912', 'name': 'Taipei Veterans General Hospital', 'awards': ['V109EP‐001']}, {'doi': '10.13039/501100011912', 'name': 'Taipei Veterans General Hospital', 'awards': ['VN109‐10']}, {'doi': '10.13039/501100011912', 'name': 'Taipei Veterans General Hospital', 'awards': ['V110EP‐001']}, {'doi': '10.13039/501100011912', 'name': 'Taipei Veterans General Hospital', 'awards': ['V110C‐027']}]

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (63)

Cited by (6)

SciLite annotations

chemicals 2
dienogest dienogest

Source provenance

crossref
last seen: 2026-06-29T06:24:35.867677+00:00
europepmc
last seen: 2026-07-31T06:09:14.520117+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-07-31T06:08:49.747907+00:00
scilite
last seen: 2026-05-18T04:25:29.313245+00:00
unpaywall
last seen: 2026-07-31T06:42:51.797318+00:00
License: CC0 · commercial use OK